Ken Griffin Clene Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.31 - $0.44 $60,963 - $86,529	-196,658 Reduced 83.6%	38,583 $13,000
Q1 2024 May 15, 2024	SELL	$0.28 - $0.53 $12,907 - $24,431	-46,098 Reduced 16.39%	235,241 $101,000
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.55 $4,254 - $8,999	16,362 Added 6.17%	281,339 $84,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.87 $730,657 - $1.38 Million	-1,588,386 Reduced 85.7%	264,977 $132,000
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.22 $1.45 Million - $2.26 Million	1,853,363 New	1,853,363 $1.63 Million
Q4 2022 Feb 14, 2023	SELL	$0.92 - $40.2 $30,376 - $1.33 Million	-33,018 Reduced 90.54%	3,451 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.33 - $73.0 $9,498 - $2.1 Million	-28,783 Reduced 44.11%	36,469 $102,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $288M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.